Clinical Trials Directory

Trials / Conditions / Recurrent Grade 3a Follicular Lymphoma

Recurrent Grade 3a Follicular Lymphoma

11 registered clinical trials studyying Recurrent Grade 3a Follicular Lymphoma — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingZanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie
NCT06859008
City of Hope Medical CenterPhase 1
SuspendedEpcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT06575686
City of Hope Medical CenterPhase 2
RecruitingMosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Fol
NCT06453044
City of Hope Medical CenterPhase 2
WithdrawnLenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym
NCT04635683
Yazeed SawalhaPhase 1
WithdrawnCpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
NCT04995536
City of Hope Medical CenterPhase 1
TerminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac
NCT04659044
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingNivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P
NCT04205409
University of WashingtonPhase 2
Active Not RecruitingPembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329
City of Hope Medical CenterPhase 1
CompletedLenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553
National Cancer Institute (NCI)Phase 1
Active Not RecruitingAnti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymp
NCT02520791
National Cancer Institute (NCI)Phase 1
Active Not RecruitingRituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphom
NCT02446457
M.D. Anderson Cancer CenterPhase 2